Page 148 - Merck Sharp News Today

PEGylated Proteins Market 2020 Global Analysis & Forecast to 2026 Market Research Report

Nina Bond and Sonya Plicque: Complaint Against Nina Bond, Dynamic Dental Solutions, Llc, Sonya Plicque ( Filing Fee $ 402 Receipt Number 0313-14816451.), Filed By Lindsey Haag.(karpf, Ari) Demand For Trial By Jury By Lindsey Haag. (lisad, ) Initial Procedural Order. Signed By Honorable Joseph F. Leeson, Jr On 1/4/21. 1/4/21 Entered And Copies E-mailed.(er, ) Summons Issued As To Nina Bond, Dynamic Dental Solutions, Llc, Sonya Plicque. E-mailed To: Counsel On 1/4/2021 (bw, ) Weekly Newsletter S...

Share this article LAS VEGAS, Jan. 12, 2021 /PRNewswire/ -- DelveInsights " Diffuse Large B-cell Lymphoma Market Research Report" report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/alg...

Jan 12, 2021 Consistent benefit regardless of CKD etiology Once, in the not-too-distant past, one could not scan the latest issue of any top-tier medical journal without finding at least one trial extolling the benefits of statin therapy, which lead many to suggest — and not always facetiously — that it was time to add statins to the water. Since late summer 2019 when the results of DAPA-HF were reported at the 2019 European Society of Cardiology Congress in Paris, SGLT2 inhibitors have dis...

 E-Mail DURHAM, N.C. - A Duke-led team of scientists has developed a bio-compatible surgical patch that releases non-opioid painkillers directly to the site of a wound for days and then dissolves away. The polymer patch provides a controlled release of a drug that blocks the enzyme COX-2 (cyclooxygenase-2,) which drives pain and inflammation. The study appears Jan. 10, 2021 in the Journal of Controlled Release. When they started "We were making hernia meshes and different antimicrobial film...

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma News provided by Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the first patient was dosed in OMS-104, an investigator-initiated Phase 2 trial evaluating TAVO™ (tavokinogene telseplasmid), the Companys intratumoral DNA plasmid-based interle...

Scott Cars L.P.: Complaint Against All Defendants ( Filing Fee $ 402 Receipt Number 0313-14813248.), Filed By Donald Boyle. (attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(rhoads, Stephen) Weekly Newsletter Sign up × By signing up you agree to receive email newsletters or alerts from Pennsylvania Record. You can unsubscribe at any time. Protected by Google ReCAPTCHA. Demand For Trial By Jury By Donald Boyle. (rhoads, Stephen) Case number 5:20-cv-06567 was filed in the U.S. D...

COVID-19 swab in lab Photo: Getty Images A Burnaby biotech company is partnering with a global pharmaceutical giant on research into advancing delivery of oral vaccines, including for COVID-19. Symvivo Corporation, a clinical-stage biotechnology company that has a proprietary bacTRL gene delivery platform, announced Tuesday that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to...

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards ...

Trial does not support early coronary CTA among higher-risk patients with suspected ACS Source: Gray A, et al. LBS.07: Randomized trials – Brain, kidney and heart. Presented at: American Heart Association Scientific Sessions; Nov. 13-17, 2020 (virtual meeting). Disclosures: The RAPID CTCA trial was funded by the National Institute for Health Research health technology assessment program. Gray reports no relevant financial disclosures. Hochman was an investigator on the ISCHEMI...